This article is more than 5 years old. Information may no longer be current.

FDA approves hyperopia application for excimer laser

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

DUBLIN, Calif. — Carl Zeiss Meditec's MEL 80 excimer laser has received premarket approval from the U.S. Food and Drug Administration to treat hyperopia, the company announced in a press release.

The MEL 80 excimer laser has already been approved for the treatment of myopia and astigmatism. The new application will allow surgeons to reduce or eliminate naturally occurring hyperopia, with or without astigmatism, in patients older than 21 years.

In a study of 369 eyes of 189 patients, 148 patients (96.7%) showed uncorrected visual acuity of 20/40 or better after 12 months, the release said. The results were presented at the American Society of Cataract and Refractive Surgery meeting.

"The MEL 80 combines premium optics with advanced excimer laser technology," Ludwin Monz, president and CEO of Carl Zeiss Meditec, said in the release. "Adding the hyperopia indication enables us to offer a complete range of treatment options to meet the demands of refractive surgeons and their patients."